Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MaaT Pharma

< Previous 1 2 Next >
MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
From MaaT Pharma
Via Business Wire
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces New Appointments to the Board and Executive Team
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
From MaaT Pharma
Via Business Wire
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
From MaaT Pharma
Via Business Wire
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
From MaaT Pharma
Via Business Wire
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
From MaaT Pharma
Via Business Wire
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma
From MaaT Pharma
Via Business Wire
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux
From MaaT Pharma
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.